Iqvia (NYSE: IQV) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Iqvia to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
95.8% of Iqvia shares are held by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.4% of Iqvia shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Iqvia has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Iqvia’s rivals have a beta of 1.47, suggesting that their average share price is 47% more volatile than the S&P 500.
This table compares Iqvia and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Iqvia and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Iqvia||$6.88 billion||$115.00 million||340.93|
|Iqvia Competitors||$217.40 million||-$39.40 million||-96.66|
Iqvia has higher revenue and earnings than its rivals. Iqvia is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations and price targets for Iqvia and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iqvia presently has a consensus price target of $106.06, suggesting a potential upside of 7.27%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 19.99%. Given Iqvia’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Iqvia has less favorable growth aspects than its rivals.
Iqvia beats its rivals on 7 of the 13 factors compared.
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.